We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > EYP-1901

News List

EyePoint Announces First Patient Dosed in Trial of EYP-1901 for Wet AMD americanpharmaceuticalreview
February 03, 2021
EyePoint Pharmaceuticals announced that the first patient has been dosed in the Phase 1 clinical trial of EYP-1901 as a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration (wet AMD).
EyePoint Reports Positive Results from GLP Toxicology Study of EYP-1901 americanpharmaceuticalreview
December 24, 2020
EyePoint Pharmaceuticals announced positive results from its good laboratory practice (GLP) preclinical toxicology study of EYP-1901, a potential six-month sustained delivery intravitreal anti-VEGF treatment using its proprietary bioerodible Durasert® ...